Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data.

BACKGROUND:  The efficacy and safety of secukinumab in patients with psoriasis has been established in randomised clinical trials. However, data on effectiveness and safety of secukinumab in Latin American real-world settings are scarce. OBJECTIVES: To evaluate the effectiveness and safety of secukinumab in real-world settings in patients with psoriasis in Latin America. METHODS: PURE is an ongoing multinational, prospective, observational study in patients with moderate-to-severe chronic plaque psoriasis in Canada and Latin America assessing the real-world safety and effectiveness of secukinumab and other approved therapies. The study enrolled (1:1) patients treated with secukinumab versus other approved therapies (other Tx) per local standard of care from 81 community- and hospital-based speciality sites (21 in Latin America). Here, we report effectiveness and safety outcomes with secukinumab and other Tx for plaque psoriasis for up to 12 months in a Latin American population. RESULTS: Overall, 187 patients were included in the analysis, 89 of whom initiated secukinumab treatment and 98 of whom received other Tx. At month 12, 84.4%, 71.1% and 53.3% of patients treated with secukinumab achieved Psoriasis Area and Severity Index (PASI) 75/90/100, respectively, compared with 66.7%, 47.9% and 29.2% of patients who received other Tx. Investigator Global Assessment (IGA) 0/1 responders in secukinumab versus other Tx were 78.3% versus 36.7% at month 3 and 81.8% versus 66.7% at month 12, respectively. Overall, the proportion of patients achieving Dermatology Life Quality Index (DLQI) 0/1 improved from 6.9% at baseline to 76.5% at month 12 in patients treated with secukinumab versus 5.6% at baseline to 54.5% at month 12 in patients on other Tx. No unexpected adverse events were reported during the 12-month observation period. CONCLUSION: Secukinumab demonstrated real-world effectiveness and improved dermatology quality-of-life in chronic plaque psoriasis patients from Latin America. TRIAL REGISTRATION: PURE: NCT02786186.

Síndrome de Kasabach-Merritt: actualización / Kasabach-Merritt's syndrome: actualization

El síndrome de Kasabach-Merritt consiste en un cuadro caracterizado por trombocitopenia, anemia hemolítica microangiopática y coagulopatía por consumo asociado a un hemangioma que crece rápidamente. La mortalidad potencial es alta, pero esto se modifica cuando el hemangioma comienza a involucionar, sea por la terapéutica instaurada o en forma espontánea. Urgencia dermatológica

Síndrome de Kasabach-Merritt: actualización / Kasabach-Merritts syndrome: actualization

El síndrome de Kasabach-Merritt consiste en un cuadro caracterizado por trombocitopenia, anemia hemolítica microangiopática y coagulopatía por consumo asociado a un hemangioma que crece rápidamente. La mortalidad potencial es alta, pero esto se modifica cuando el hemangioma comienza a involucionar, sea por la terapéutica instaurada o en forma espontánea. Urgencia dermatológica (AU)